Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

RGNT

Regentis Biomaterials Ltd

Jan 16 • 11:25AM ET

7.42

-0.28 -3.66 %

Healthcare • Medical Instruments & Supplies • Israel • AMEX

Index	-	P/E	-	EPS (ttm)	-1.15	Insider Own	42.78%	Shs Outstand	4.93M	Perf Week	12.06%
Market Cap	38.43M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.96M	Perf Month	7.67%
Enterprise Value	81.50M	PEG	-	EPS next Q	-	Inst Own	6.36%	Short Float	0.09%	Perf Quarter	-
Income	-5.66M	P/S	-	EPS this Y	-	Inst Trans	0.00%	Short Ratio	0.09	Perf Half Y	-
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-1676.79%	Short Interest	0.00M	Perf YTD	10.07%
Book/sh	-8.99	P/C	202.25	EPS next 5Y	-	ROE	-	52W High	7.77 -4.53%	Perf Year	-
Cash/sh	0.04	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	5.75 29.02%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.67% 7.90%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	72.10%	Oper. Margin	-	ATR (14)	0.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.05	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.99	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.05	EPS Q/Q	-	SMA20	10.22%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	8.22%	Rel Volume	27.91	Prev Close	7.70
Employees	10	LT Debt/Eq	-	Earnings	-	SMA200	8.22%	Avg Volume	28.22K	Price	7.42
IPO	Dec 04, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	260,015	Change	-3.66%

Jan-06-26 08:21AM	Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation (ACCESSWIRE)
Dec-18-25 08:35AM	Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC (ACCESSWIRE)
Dec-05-25 04:10PM	Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering (GlobeNewswire)
Dec-03-25 07:23PM	Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering (GlobeNewswire)

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNT

Regentis Biomaterials Ltd

Upgrade your FINVIZ experience